The study’s objective was to evaluate the utility of urinary IGFBP-7, urinary TIMP-2, and serum transgelin levels as biomarkers for the prediction of renal impairment in patents with multiple myeloma. This evidence concerns the gene IGFBP7 and plasma cell myeloma.